Completion of the pharmacokinetics study of AD04 enables the end-of-Phase 2 (EOP2) interaction with the FDA, a crucial step toward advancing to Phase 3 trials. Study results support the planned ...

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...

Study completion enables an End-of-Phase 2 FDA meeting and strengthens ... ADIL announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable ...

Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable bioavailability, dose proportionality, no food effect, and a ...

“The human PK model of GD2-SADA informed the design and initial dosing regimen of our ongoing first-in-human (FIH) Phase 1 Trial (Trial 1001),” said Norman LaFrance, M.D., Chief Development Officer.

Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated ...

Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administrationPhase 1/2 clinical data for VYD2311 to date are positiv ...